サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：呼吸障害治療薬の世界市場-2022-2029
市場調査レポート
商品コード
1176600

呼吸障害治療薬の世界市場-2022-2029

Global Breathing Disorder Treatment Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
呼吸障害治療薬の世界市場-2022-2029
出版日: 2022年12月26日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

呼吸障害治療薬は、COPDや喘息など、いくつかの呼吸器または呼吸障害の治療に使用される薬物です。これらの医薬品は、炎症を抑え、気道を開くことで呼吸を楽にするものです。大気汚染や粉塵への高い曝露、喫煙の増加により、これらの薬剤の採用が促進されるでしょう。

市場力学

呼吸障害治療薬の市場は、喘息やCOPDなどの呼吸障害を持つ人々の増加、先端技術の台頭、研究開発投資の増加、新興国市場での医療インフラへの投資の増加によって牽引されています。

呼吸障害治療薬の普及率の上昇と研究開発への投資の増加は、市場の成長を促進すると予想されます。

呼吸障害治療薬市場は、技術の進歩の高まり、呼吸障害治療の需要の増加、研究開発投資の急増、喘息、COPD、慢性気管支炎などの慢性呼吸障害の増加、新興国の医療インフラの進歩とともに最新技術を用いた新薬の改良によって牽引されています。WHOによると、慢性閉塞性肺疾患（COPD）は世界で2億人近くが罹患していると言われています。現在、慢性疾患の治療に対する政府機関の資金援助が増加していることが、市場の成長を後押ししています。例えば、欧州連合では、COPDの直接費用は医療費全体の約6％であり、呼吸器疾患の総費用の56％近くを占めています。

技術の進歩により、呼吸障害治療薬の採用が増加しています。呼吸器疾患の増加、呼吸障害治療のための気管支拡張薬や抗菌薬に関する意識の高まり、政府や民間企業による医療支出の増加は、インフラ投資の増加につながり、呼吸器疾患治療市場を促進する可能性があります。

さまざまな新規製品の発売や調査研究は、市場の成長に寄与しています。例えば、2022年3月14日、ノバルティス傘下のサンドは、英国を拠点とするドラッグデリバリーおよび医療機器開発会社であるCoalesce Product Development Limitedの買収に成功したと発表しました。サンドは、この買収により、既存の呼吸器系医薬品のポートフォリオを構築するのに役立つコアレッセの重要な能力を獲得しました。

呼吸障害治療薬に伴う副作用が市場成長の妨げになることが予想されます。

呼吸障害治療薬の世界市場は、呼吸障害治療の副作用によって抑制されています。副作用には、口の渇き、震え、めまい、喉の炎症または掻痒感、鼻水、胃のむかつきなどがあります。

呼吸障害治療薬の承認に関する厳しい規則や規制、気管支拡張剤に伴う震え、神経緊張、動悸、筋肉のけいれんなどの有害事象が市場の成長を妨げています。

COVID-19の影響分析

パンデミックは、世界の財政的な期待、業務、危機対応戦略にプラスの影響を与えています。COVID-19の発生は、ヘルスケア産業に深刻な影響を与えました。呼吸障害治療市場は、COVIDの症例が増加したため、様々な研究、臨床試験が本格的に開始され、COVIDによる莫大な利益を経験しました。主要メーカーは、様々な研究や臨床試験を開始しました。複数のイニシアチブ、製品の発売、コラボレーション、合併が世界中で起こっており、市場の成長を後押ししています。例えば、2021年12月17日、Amgenは、AstraZenecaとAmgenのTezspire（tezepelumab-ekko）が、12歳以上の小児および成人患者、重度の喘息によるアドオン維持治療で米国食品医薬品局（FDA）から承認されたと発表しました。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 呼吸障害治療薬の普及率上昇
      • 研究開発費の増加
      • 技術的進歩の増加
    • 抑制要因
      • 呼吸障害治療薬に関連する副作用
    • ビジネスチャンス
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • プライシング分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 薬剤クラス別

  • 抗菌剤
    • トブラマイシン（TOBI）
    • ペンタミジン（ネブペント）
    • リバビリン（ビラゾール）
  • 副腎皮質ホルモン剤
    • ブデソニド
    • ラセミエピネフリン
  • 気管支拡張剤
    • メタプロテレノール（アルペント）
    • イプラトロピウム（アトロベント）
    • ホルモテロール（パーフォミスト）
    • アルフォルモテロール（ブロバナ）
    • レバルブテロール塩酸塩（ゾペネックス）
    • 硫酸アルブテロール（アキュネブ）
  • 抗ヒスタミン剤
    • ザフィルルカスト
    • ジレイトン
    • モンテルカスト
  • 呼吸器官刺激薬
    • セチリジン
    • ロラチジン
  • その他

第8章 効能・効果別

  • 慢性閉塞性肺疾患（COPD）
  • 気管支喘息
  • 嚢胞性線維症
  • 肺高血圧症
  • 肺がん
  • アレルギー性鼻炎
  • 特発性肺線維症
  • その他

第9章 販売チャネル別

  • 病院内薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第12章 企業プロファイル

  • F. Hoffmann-La Roche
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • AstraZeneca
  • GSK plc
  • Abbott Laboratories
  • Amgen Inc.
  • Novartis AG
  • Medtronic plc
  • Dr. Reddy's Laboratories Ltd.
  • Bayer AG
  • Biogen

第13章 呼吸障害治療薬の世界市場-DataM

目次
Product Code: DMPH4725

Market Overview

Breathing disorder drugs are medications used for treating several respiratory or breathing disorders, such as COPD and asthma. These medicines make breathing easier by reducing inflammation and opening the airways. High exposure to air pollution and dust and increased smoking will enhance the adoption of these drugs.

Market Dynamics

The market for breathing disorder treatment is driven by the increase in the number of people with respiratory disorders, including asthma and COPD, rising advanced technology, increasing research and development investments and the rising investment in healthcare infrastructure in emerging markets.

The rising adoption of breathing disorders drugs and increasing investment in research and development are expected to drive the market's growth.

The breathing disorder treatment market is driven by rising advancements in technology, an increase in demand for breathing disorder drugs, a surge in research and development investments, an increasing number of chronic respiratory disorders such as asthma, COPD, chronic bronchitis, and improvements in novel drugs using the latest technology along with advances in medical infrastructure in emerging markets. According to the WHO, chronic obstructive pulmonary disease (COPD) affects nearly 200 million people globally. Today, rising funding by government organizations for the treatment of chronic diseases will boost the market growth. For instance, in European Union, the direct cost of COPD is around 6% of total health expenditure, accounting for nearly 56% of the total cost of respiratory diseases.

Technological advances have resulted in increasing breathing disorder drugs adoption. The rising number of respiratory disorders, increasing awareness about bronchodilators and antimicrobial drugs for treating respiratory disorders and rising healthcare expenditure by governments and the private sector could lead to higher infrastructure investments and drive the breathing disorder treatment market.

Various novel product launches and research studies contribute to the market's growth. For instance, in March 14, 2022, Sandoz, a Novartis subsidiary, announced its successful acquisition of Coalesce Product Development Limited, a UK-based drug delivery and medical device development company. Sandoz, with this acquisition, acquired the significant capabilities of Coalesce that can help in building on its existing respiratory medicines portfolio.

The side effects associated with breathing disorder treatment drugs are expected to hamper the market's growth.

The global market for breathing disorder treatment is restrained by the side effects of drugs for breathing disorder treatment. Side effects include dry mouth, tremors, dizziness, irritated or scratchy throat, runny nose and upset stomach.

Stringent rules and regulations for respiratory disorders treatment drugs approval and adverse events such as trembling, nervous tension, palpitations, muscle cramps, and others associated with bronchodilators hinder the market growth.

COVID-19 Impact Analysis

The pandemic has positively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely affected the healthcare industry. The breathing disorder treatment market has experienced huge profits due to COVID as various research, and clinical trials got started in full swing due to the increasing cases of COVID. Key manufacturers have started various research and clinical trials. Multiple initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in December 17, 2021, Amgen announced that AstraZeneca and Amgen's Tezspire (tezepelumab-ekko) had been approved by the U.S. Food and Drug Administration (FDA) for pediatric and adult patients aged 12 years and older, add-on maintenance treatment with severe asthma.

Segment Analysis

The bronchodilators segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The bronchodilators segment is the highest market holder in the global breathing disorder treatment market. The global breathing disorder treatment market is segmented on the basis of drug class in antimicrobial, corticosteroid, bronchodilator, antihistamines, respiratory stimulants and others. The bronchodilator segment is the largest market shareholder due to its rising adoption and demand due to increased respiratory disorders, technological advancements, and novel product launches.

These drugs are the most used inhaled medications. The bronchodilators can be further divided into parasympatholytic (anticholinergic) drugs and sympathomimetic (adrenergic) drugs and are classified as long-acting or short-acting. Anticholinergic drugs block the parasympathetic system, while adrenergic drugs basically stimulate the sympathetic nervous system. Adrenergic agents cause bronchodilation, and anticholinergic drugs generally block bronchoconstriction. Short-acting bronchodilators are efficacious for 4 to 6 hours, while long-acting drugs generally last about 12 hours.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in July 7, 2020, Novartis announced that its Enerzair Breezhaler (glycopyrronium bromide, indacaterol acetate, and mometasone furoate) first LABA/long-acting muscarinic antagonist fixed-dose combination had been approved by the European Commission (EC) for asthma treatment in adult patients with a combination of a high-dose of an inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA), who experienced asthma exacerbations.

Geographical Analysis

North America holds the largest market share in the global breathing disorder treatment market.

North America dominates the global breathing disorder treatment market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US. The market's significant size is attributed to the high medical expenditure. According to the Office of Disease Prevention and Health Promotion (ODPHP), around 14.8 million adults suffered from chronic obstructive pulmonary disease (COPD) in the United States in 2020. And 25 million have asthma.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of medications for breathing disorder treatment in asthma, and COPD, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the breathing disorder treatment market.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in March 23, 2020, Bayer announced its license agreement and research collaboration with Curadev, a domestic drug discovery firm for discovering novel drug candidates for cardiovascular, lung and inflammatory diseases treatment.

Competitive Landscape

The breathing disorder treatment market is highly competitive with local and global companies' presence. F. Hoffmann-La Roche, AstraZeneca, GSK plc, Abbott Laboratories, Amgen Inc., Novartis AG, Medtronic plc, Dr. Reddy's Laboratories Ltd., Bayer AG, Biogen and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in February 16, 2022, Mankind Pharma announced that it had signed an acquisition agreement with Dr. Reddy's Laboratories for two brands, Daffy and Combihale. Combihale is utilized for treating chronic obstructive pulmonary disease and asthma.

Novartis AG.

Overview: Novartis is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.

Product Portfolio:

Arcapta Neohaler: Arcapta Neohaler is the once-daily, 24-hour long-acting beta2-agonist that has been approved for airflow obstruction in COPD patients' maintenance treatment.

Key Development: In November 19, 2020, Novartis announced its exclusive global collaboration and license agreement with Mesoblast for the development, manufacturing and selling of remestemcel-L for acute respiratory distress syndrome (ARDS) treatment, including that associated with COVID-19.

The global breathing disorder treatment market report would provide access to approx.: 45+ market data tables, 40+ figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising adoption of breathing disorder drugs
      • 4.1.1.2. Increasing research and development expenditure
      • 4.1.1.3. Rising technological advancements
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with the breathing disorder treatment drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Antimicrobial *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.2.3. Tobramycin (TOBI)
    • 7.2.4. Pentamidine (Nebupent)
    • 7.2.5. Ribavirin (Virazole)
  • 7.3. Corticosteroid
    • 7.3.1. Budesonide
    • 7.3.2. Racemic epinephrine
  • 7.4. Bronchodilator
    • 7.4.1. Metaproterenol (Alupent)
    • 7.4.2. Ipratropium (Atrovent)
    • 7.4.3. Formoterol (Perforomist)
    • 7.4.4. Arformoterol (Brovana)
    • 7.4.5. Levalbuterol HCl (Xopenex)
    • 7.4.6. Albuterol sulfate (AccuNeb)
  • 7.5. Antihistamines
    • 7.5.1. Zafirlukast
    • 7.5.2. Zileuton
    • 7.5.3. Montelukast
  • 7.6. Respiratory stimulants
    • 7.6.1. Cetirizine
    • 7.6.2. Loratidine
  • 7.7. Others

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. Chronic Obstructive Pulmonary Disease (COPD) *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Asthma
  • 8.4. Cystic Fibrosis
  • 8.5. Pulmonary Hypertension
  • 8.6. Lung Cancer
  • 8.7. Allergic Rhinitis
  • 8.8. Idiopathic Pulmonary Fibrosis
  • 8.9. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. F. Hoffmann-La Roche *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. AstraZeneca
  • 12.3. GSK plc
  • 12.4. Abbott Laboratories
  • 12.5. Amgen Inc.
  • 12.6. Novartis AG
  • 12.7. Medtronic plc
  • 12.8. Dr. Reddy's Laboratories Ltd.
  • 12.9. Bayer AG
  • 12.10. Biogen

LIST NOT EXHAUSTIVE

13. Global Breathing Disorder Treatment Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Indication
  • 13.3. Contact Us